Patents Assigned to Verastem, Inc.
-
Patent number: 11873296Abstract: Solid forms of a dual RAF/MEK inhibitor, pharmaceutical compositions thereof, oral dosage forms thereof, and methods of treating cancer are described herein. Also provided herein are processes for preparing solid forms of a dual RAF/MEK inhibitor and pharmaceutical compositions and oral dosage forms thereof.Type: GrantFiled: December 29, 2022Date of Patent: January 16, 2024Assignee: VERASTEM, INC.Inventor: Farzaneh Seyedi
-
Patent number: 11564927Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.Type: GrantFiled: November 25, 2019Date of Patent: January 31, 2023Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
-
Patent number: 10532056Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.Type: GrantFiled: June 29, 2016Date of Patent: January 14, 2020Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
-
Patent number: 10406158Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: GrantFiled: April 2, 2018Date of Patent: September 10, 2019Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Patent number: 9962385Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: GrantFiled: February 6, 2015Date of Patent: May 8, 2018Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Patent number: 9505719Abstract: An improved synthesis of a class of inhibitor of Focal Adhesion Kinase (FAK) is provided, wherein use of an expensive palladium-based catalyst is reduced and reaction yields and product purities are improved. Two key reactions of coupling of aryl halides with anilines are optimized with the surprising discovery that the palladium-based catalyst can be dispensed with entirely in one of the reactions. The invention also provides the use of the FAK-inhibitory compounds in the treatment of inflammatory and immune disorders and of arthritis.Type: GrantFiled: August 7, 2013Date of Patent: November 29, 2016Assignee: VERASTEM, INC.Inventors: Yixiong Lei, Carl Henry Behrens, Hui-Yin Li, Connie L. Sun
-
Patent number: 9375402Abstract: The invention is directed to formulations of bioactive compounds of limited water solubility, inhibitors of focal adhesion kinase (FAK) of the 2,4-diaminopyridine class, adapted for oral administration to patients. The formulations are self-emulsifying in the gastrointestinal tract of the patients, providing enhanced absorption and bioavailability of the bioactive compounds as dispersions or emulsions in an oil base. For example, esters of PEG-ylated glycerol can be used as the oil, in conjunction with surfactants such as lecithin and TEPG succinate and solubilizers such as PEG 400 to provide useful oral formulations for administration to patients having a malcondition wherein inhibition of FAK is medically indicated, such as cancer or arthritis.Type: GrantFiled: August 14, 2013Date of Patent: June 28, 2016Assignee: VERASTEM, INC.Inventors: Andrew Xian Chen, Yali J. Tsai
-
Patent number: 9138437Abstract: The present invention relates to a purine compound useful as a kinase inhibitor. The compound has the structure: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 7, 2014Date of Patent: September 22, 2015Assignee: Verastem, Inc.Inventors: DiZhong Chen, Meredith Williams
-
Publication number: 20150190346Abstract: This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.Type: ApplicationFiled: January 9, 2015Publication date: July 9, 2015Applicants: VERASTEM, INC., PFIZER, INC.Inventors: Mahesh Padval, Paul Okwabi Nkansah
-
Publication number: 20150105382Abstract: The present invention relates to a purine compound useful as a kinase inhibitor.Type: ApplicationFiled: May 7, 2014Publication date: April 16, 2015Applicant: VERASTEM, INC.Inventors: DiZhong Chen, Meredith Williams
-
Publication number: 20150080368Abstract: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Applicant: VERASTEM, INC.Inventors: Michael Joseph Luzzio, Kevin Daniel Freeman-Cook, Samit Kumar Bhattacharya, Matthew Merrill Hayward, Catherine Angela Hulford, Christopher Lowell Autry, Xumiao Zhao, Jun Xiao, Kendra Louise Nelson
-
Patent number: 8754080Abstract: The present invention relates to a purine compound useful as a kinase inhibitor. The compound has the structure (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 3, 2009Date of Patent: June 17, 2014Assignee: Verastem, Inc.Inventors: DiZhong Chen, Meredith Williams
-
Patent number: 8722884Abstract: The present invention relates to salts, solvates and substoichiometric solvates of N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-N-methylmethanesulfonamide. The invention also provides pharmaceutical compositions comprising such complexes, as well as methods of treating abnormal cell growth by administering the complexes of the invention.Type: GrantFiled: November 20, 2006Date of Patent: May 13, 2014Assignee: Verastem, Inc.Inventors: John Charles Kath, Michael Joseph Luzzio, Susan La Greca, Nandini Chaturbhai Patel
-
Publication number: 20140066620Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.Type: ApplicationFiled: November 11, 2013Publication date: March 6, 2014Applicant: VERASTEM, INC.Inventors: Harish K. Mysore, Meredith Williams
-
Patent number: 8609838Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumors and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.Type: GrantFiled: July 20, 2012Date of Patent: December 17, 2013Assignee: Verastem, Inc.Inventors: Harish K. Nagaraj, Meredith Williams